This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Maxygen Reports Fourth Quarter And Year End 2011 Financial Results

Maxygen, Inc. (Nasdaq:MAXY), a biopharmaceutical company, today announced financial and business results for the quarter and year ended December 31, 2011.

Fourth Quarter 2011 Financial Results

Maxygen reported a net loss attributable to Maxygen, Inc. of $2.2 million, or $0.08 per basic and diluted share, for the fourth quarter of 2011, compared to net income attributable to Maxygen, Inc. of $69.9 million, or $2.40 per basic share and $2.39 per diluted share, for the same period in 2010. The net loss for the fourth quarter of 2011 primarily reflects a loss from continuing operations before income taxes of $2.8 million, plus a net tax benefit of $559,000. The net tax benefit consists of a $1.2 million tax benefit reported within continuing operations, partially offset by a $593,000 tax expense recorded within discontinued operations. The net income for the 2010 period primarily reflects a gain of $53.2 million Maxygen recognized in connection with its distribution to stockholders of shares of Codexis, Inc. common stock in December 2010 and a gain of $20.0 million recognized in connection with Maxygen’s sale to Codexis of the intellectual property assets associated with the MolecularBreeding™ directed evolution platform. These gains were partially offset by a $2.4 million loss from operations.

Maxygen had total revenue of $3,000 in the fourth quarter of 2011, compared to $529,000 of revenue for the same period in 2010. Revenue in the 2011 period consisted of miscellaneous licensing fees. Revenue in the 2010 period consisting primarily of a $525,000 payment received from Altravax, Inc. in December 2010 in connection with its acquisition of substantially all of the company’s vaccines assets in January 2010.

Total operating expenses from continuing operations for the fourth quarter of 2011 were $2.8 million, compared to operating expenses of $2.9 million for the same period in 2010. The decrease in operating expenses primarily reflects a decreases in stock based compensation expense and external legal costs, partially offset by a lower allocation of administrative costs charged to Perseid Therapeutics LLC, the company’s former majority-owned subsidiary, under a transition service agreement. For the fourth quarter of 2010, Maxygen reported a negative research and development expense of $129,000 primarily due to a credit related to the reclassification of research and development expenses associated with discontinued operations from a prior period.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,096.90 -106.47 -0.58%
S&P 500 2,098.53 -9.25 -0.44%
NASDAQ 4,967.1410 -12.76 -0.26%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs